Is Amazon an AI Stock?
With the market starting to look skittish on pure-play AI…
Buy
57
SNDX Quote, Financials, Valuation and Earnings
Last price:
$19.76
Seasonality move
:
16.56%
Day range:
$19.31 - $20.03
52-week range:
$8.58 - $20.20
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
15.24x
P/B ratio:
14.84x
Volume:
1.9M
Avg. volume:
3.3M
1-year change:
18.59%
Market cap:
$1.7B
Revenue:
$23.7M
EPS (TTM):
-$3.62
Analysts' Opinion
-
Consensus RatingSyndax Pharmaceuticals, Inc. has received a consensus rating of Buy. The company's average rating is a Buy based on 12 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $39.31, Syndax Pharmaceuticals, Inc. has an estimated upside of 99.43% from its current price of $19.71.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $27.00 representing 100% downside risk from its current price of $19.71.
Fair Value
-
According to the consensus of 12 analysts, Syndax Pharmaceuticals, Inc. has 99.43% upside to fair value with a price target of $39.31 per share.
SNDX vs. S&P 500
-
Over the past 5 trading days, Syndax Pharmaceuticals, Inc. has overperformed the S&P 500 by 1.33% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Syndax Pharmaceuticals, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Syndax Pharmaceuticals, Inc. has grown year-over-year revenues for 2 quarters straight. In the most recent quarter Syndax Pharmaceuticals, Inc. reported revenues of $45.9M.
Earnings Growth
-
Syndax Pharmaceuticals, Inc. has grown year-over-year earnings for 1 quarter straight. In the most recent quarter Syndax Pharmaceuticals, Inc. reported earnings per share of -$0.70.
Enterprise value:
1.6B
EV / Invested capital:
3.52x
Price / LTM sales:
15.24x
EV / EBIT:
--
EV / Revenue:
14.55x
PEG ratio (5yr expected):
-0.26x
EV / Free cash flow:
-5.22x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$106.5M
Return On Assets:
-53%
Net Income Margin (TTM):
-279.31%
Return On Equity:
-136.36%
Return On Invested Capital:
-61.68%
Operating Margin:
-125.19%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | -- | $16M | $111.6M | $12.5M | $45.9M | |
| Gross Profit | -$383K | $12.5M | $106.5M | $12.5M | $43.8M | |
| Operating Income | -$194.1M | -$321.2M | -$306.7M | -$89.6M | -$57.4M | |
| EBITDA | -$193.7M | -$321.2M | -$306.7M | -$89.6M | -$57.4M | |
| Diluted EPS | -$2.59 | -$3.63 | -$3.62 | -$0.98 | -$0.70 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $238.3M | $357.6M | $381M | $414.8M | $529.8M | |
| Total Assets | $239.5M | $359.7M | $399.2M | $425.8M | $551.8M | |
| Current Liabilities | $28.7M | $20.8M | $39.2M | $59.4M | $114.2M | |
| Total Liabilities | $40.5M | $21.6M | $40M | $59.4M | $436.4M | |
| Total Equity | $199M | $338.1M | $359.2M | $366.4M | $115.4M | |
| Total Debt | $21.6M | $786K | $875K | $12K | $345.1M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$142.1M | -$258.9M | -$310.9M | -$62.3M | -$70.5M | |
| Cash From Investing | -$3.7M | $32.9M | -$60.5M | $86.8M | $72.4M | |
| Cash From Financing | $169.2M | $264.4M | $355.2M | $3.1M | $6.3M | |
| Free Cash Flow | -$142.1M | -$258.9M | -$311M | -$62.3M | -$70.7M | |
SNDX
Sector
Market Cap
$1.7B
$28.4M
Price % of 52-Week High
97.57%
50.35%
Dividend Yield
0%
0%
Shareholder Yield
-6.01%
-1.32%
1-Year Price Total Return
18.59%
-22.19%
Beta (5-Year)
0.476
0.521
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$19.25
200-day SMA
Buy
Level
$13.25
Bollinger Bands (100)
Buy
Level
0 - 0
Chaikin Money Flow
Sell
Level
--
20-day SMA
Buy
Level
$17.52
Relative Strength Index (RSI14)
Buy
Level
66.60
ADX Line
Neutral
Level
0
Williams %R
Sell
Level
-10.5376
50-day SMA
Buy
Level
$16.01
MACD (12, 26)
Buy
Level
1.16
25-day Aroon Oscillator
Buy
Level
84
On Balance Volume
Neutral
Level
--
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-1.489)
Sell
CA Score
(Annual)
Level (-2.146)
--
Beneish M-Score
(Annual)
Level (--)
Sell
Momentum Score
Level (2)
Sell
Ohlson Score
Level (2.7256)
Buy
Piotroski F Score
(Annual)
Level (4)
Buy
Quality Ratio Score
Level (5)
Buy
Fundamental Score
Level (3)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Syndax Pharmaceuticals, Inc. engages in the development of cancer therapies. Its products include SyndAccess, Revuforj, Niktimvo, and IncyteCARES. The company was founded by Richard A. Heyman, Eckard Weber, Peter Ordentlich, Ronald M. Evans and Michael Downes on October 11, 2005 and is headquartered in New York, NY.
Stock Forecast FAQ
In the current month, SNDX has received 12 Buy ratings 0 Hold ratings, and 0 Sell ratings. The SNDX average analyst price target in the past 3 months is $39.31.
-
Where Will Syndax Pharmaceuticals, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Syndax Pharmaceuticals, Inc. share price will rise to $39.31 per share over the next 12 months.
-
What Do Analysts Say About Syndax Pharmaceuticals, Inc.?
Analysts are divided on their view about Syndax Pharmaceuticals, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Syndax Pharmaceuticals, Inc. is a Sell and believe this share price will drop from its current level to $27.00.
-
What Is Syndax Pharmaceuticals, Inc.'s Price Target?
The price target for Syndax Pharmaceuticals, Inc. over the next 1-year time period is forecast to be $39.31 according to 12 Wall Street analysts, 12 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is SNDX A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Syndax Pharmaceuticals, Inc. is a Buy. 12 of 12 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of SNDX?
You can purchase shares of Syndax Pharmaceuticals, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Syndax Pharmaceuticals, Inc. shares.
-
What Is The Syndax Pharmaceuticals, Inc. Share Price Today?
Syndax Pharmaceuticals, Inc. was last trading at $19.76 per share. This represents the most recent stock quote for Syndax Pharmaceuticals, Inc.. Yesterday, Syndax Pharmaceuticals, Inc. closed at $19.71 per share.
-
How To Buy Syndax Pharmaceuticals, Inc. Stock Online?
In order to purchase Syndax Pharmaceuticals, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get SNDX Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
SNDX
Sector
P/E ratio
--
23.66x
PEG ratio
-0.26x
-0.01x
P/B ratio
14.84x
1.84x
Price / LTM sales
15.24x
1.60x
Growth Metrics
SNDX
Sector
Revenue growth
266.97%
4.85%
Earnings growth
28.82%
11.15%
Revenue (5-year growth)
73.25%
6.45%
Earnings forecast
-$0.71
-$0.20
Profitability
SNDX
Sector
Profitability FY 2024
$22.8M
$3.6M
Return on invested capital
-61.68%
-30.98%
Return on assets
-53%
-27.62%
Return on equity
-136.36%
-36.69%
Earnings Date
Last Earnings Date
Nov
3
Next Earnings Date
Mar
2
Estimated Next Earnings Date
Feb
2
Balance Sheet
SNDX
Sector
Total cash
$436M
$27.2M
Short term investments
$428.8M
$25.7M
Total assets
$724.8M
$79.9M
Long term debt
$345.1M
$4.1M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Google Vs NVIDIA Stock: Which Is Best?
Alphabet (NASDAQ:GOOGL) and NVIDIA (NASDAQ:NVIDIA) are two of the market’s…
How High Could NVIDIA Stock Go?
NVIDIA (NASDAQ:NVDA) has been one of the best stocks to…
Stock Ideas
Buy
51
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 61x
Buy
64
Is AAPL Stock a Buy?
Market Cap: $4.2T
P/E Ratio: 38x
Buy
69
Is GOOG Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 40x
Alerts
Sell
47
PSTG alert for Dec 4
Pure Storage, Inc. [PSTG] is up 5.05% over the past day.
Sell
41
SMX alert for Dec 4
SMX (Security Matters) Plc [SMX] is up 154.74% over the past day.
Sell
43
HY alert for Dec 4
Hyster-Yale, Inc. [HY] is up 1.92% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
